Breaking News Instant updates and real-time market news.

MDCO

The Medicines Co.

$38.51

0.32 (0.84%)

, ALNY

Alnylam

$70.30

1.73 (2.52%)

16:40
10/05/16
10/05
16:40
10/05/16
16:40

Medicines Co. gives update after Alnylam drug halt, says finds no safety issues

The Medicines Company (MDCO) provided a progress update on the ongoing ORION-1 study of PCSK9si, its investigational first-in-class PCSK9 synthesis inhibitor. ORION-1 is a Phase II trial in patients with atherosclerotic cardiovascular disease or ASCVD-risk equivalents and elevated LDL-C despite maximum tolerated doses of LDL-C lowering therapies. The study exceeded its enrollment target of 480 patients ahead of schedule, enrolling a total of 501 patients between January 21 and June 2. An interim analysis of Day 90 follow-up for all 501 patients will be conducted and presented at the AHA Scientific Sessions on November 15. In addition, the company anticipates that top-line data from Day 180 follow-up for up to 200 patients will be presented at the late-breaking clinical trial session and Day 180 follow-up in all 501 patients will be completed, analyzed and top-line results disclosed before the end of 2016. The independent data monitoring committee has raised no safety concerns and made no safety-related study recommendations through its most recent review on August 26. Moreover, based upon the company's review of blinded safety data through September 29, the most recent date for which safety data has been made available, no material safety issue and, in particular, no drug-related neuropathy, elevation of liver enzymes or changes in renal function, has been observed. At that date, the 501 study patients had treatment exposure of between 4 and 8 months. The statements follow Alnylam's (ALNY) development halt on its revusiran drug. Alnylam is partnered with Medicines Co. on the ALN-PCSsc program.

MDCO

The Medicines Co.

$38.51

0.32 (0.84%)

ALNY

Alnylam

$70.30

1.73 (2.52%)

  • 14

    Oct

  • 06

    Nov

MDCO The Medicines Co.
$38.51

0.32 (0.84%)

05/13/16
JEFF
05/13/16
NO CHANGE
Target $43
JEFF
Buy
The Medicines Co. could rally $4/share on positive data, says Jefferies
Jefferies analyst Biren Amin says The Medicines Co. has a "catalyst-rich" second half of 2016, including the Phase III trials of Carbavance in complicated urinary tract infections and carbapenem resistant enterobacteriaceae infections. The analyst expects both of the trials will be successful and show non-inferiority leading to potential FDA approval. Amin thinks shares could move $3 to $4 per share on positive data readout. He keeps a Buy rating on The Medicines Co. with a $43 price target.
07/11/16
JEFF
07/11/16
NO CHANGE
Target $43
JEFF
Buy
Jefferies views The Medicines Co. ruling as positive surprise
Jefferies analyst Biren Amin views today's Court of Appeals ruling as a "positive surprise" for The Medicines Company. The ruling "breathes potential life" into the company's Angiomax patents, Amin tells investors in a research note. He expects Hospira to file an appeal within 90 days. The analyst has a Buy rating on The Medicines Co. with a $43 price target.
08/02/16
EVER
08/02/16
NO CHANGE
EVER
Buy
Pfizer shelves oral PCSK9, a Medicines Co. competitor, says Evercore ISI
Evercore ISI analyst Umer Raffat said Pfizer (PFE) management does not thin the profile for oral PCSK9 will be competitive with the strong efficacy of antibodies and have moved other interesting products forward. Raffat said some Medicines Co. (MDCO) investors had worried that a potential oral PCSk9 from Pfizer could greatly reduce enthusiasm for an every-6-month PCSk9 from MDCO. The analyst said the next catalyst for The Medicines Co. is A1 Milano readout this month. Raffat rates The Medicines Co. a Buy with a $52 price target.
09/09/16
LEER
09/09/16
NO CHANGE
LEER
Leerink updates therapeutics best ideas for 2016
In a note to investors this morning, Leerink has updated its best ideas for 2016 from the firm's five therapeutics analysts. The list includes Alexion (ALXN), Dermira (DERM), Intra-Cellular (ITCI), Sanofi (SNY), Allergan (AGN), Alnylam (ALNY), Innate Pharma (IPHYF), The Medicines Co. (MDCO), and Ophthotech (OPHT).
ALNY Alnylam
$70.30

1.73 (2.52%)

08/22/16
WEDB
08/22/16
NO CHANGE
WEDB
Intellia Therapeutics data positive, says Wedbush
Wedbush analyst David Nierengarten says that additional data on Intella's (NTLA) TTR program in mice was "meaningful" and indicates that the program compares favorably with competing products. The analyst says that competing programs, including those of Alnylam (ALNY) and Ionis (IONS) have shown "only a transient benefit." He reiterates a $38 price target and Outperform rating on Intella.
09/15/16
09/15/16
INITIATION
Target $82

Underperform
FBR calls Alexion overvalued, starts shares at Underperform
FBR Capital analyst Christopher James initiated coverage of Alexion Pharmaceuticals (ALXN) with an Underperform rating and $82 price target. The biotech focused on patients with ultra-rare disorders closed yesterday up $2.63 to $129.42. Alexion shares are overpriced as the company is facing a competitive near-term landscape, particularly from Alnylam's (ALNY) ALN-CC5, James tells investors in a research note. Further, near-term expansion into additional indications will be challenging given the recent failed study with eculizumab in refractory generalized myasthenia gravis, the analyst contends. He also sees possible pricing pressures from biosimilars, including an Amgen (AMGN) biosimilar product in development. James this morning also initiated Achillion Pharmaceuticals (ACHN) and Arena Pharmaceuticals (ARNA) with Outperform ratings.
09/28/16
JANY
09/28/16
INITIATION
Target $74
JANY
Neutral
Alnylam initiated with a Neutral at Janney Capital
Janney Capital analyst Roy Buchanan initiated Alnylam with a Neutral and a $74 fair value estimate. The analyst is not confident about the outcome for the pivotal study for patisiran in transthyretin familial amyloid neuropathy, expected in about 12 months, and give patisiran a 50% chance of success.

TODAY'S FREE FLY STORIES

HTGM

HTG Molecular

$3.64

-0.07 (-1.89%)

, QGEN

Qiagen

$32.65

0.46 (1.43%)

08:28
01/16/18
01/16
08:28
01/16/18
08:28
Hot Stocks
HTG announces third statement of work for new clinical assay development program »

HTG Molecular Diagnostics…

HTGM

HTG Molecular

$3.64

-0.07 (-1.89%)

QGEN

Qiagen

$32.65

0.46 (1.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RDHL

RedHill Biopharma

$5.17

-0.03 (-0.58%)

08:28
01/16/18
01/16
08:28
01/16/18
08:28
Hot Stocks
RedHill Biopharma's Phase II study of Bekinda met primary endpoint »

RedHill Biopharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

DERM

Dermira

$27.44

0.74 (2.77%)

08:28
01/16/18
01/16
08:28
01/16/18
08:28
Recommendations
Dermira analyst commentary  »

Dermira should rally on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jun

SPB

Spectrum Brands

$120.48

-0.14 (-0.12%)

, ENR

Energizer

$51.62

0.15 (0.29%)

08:27
01/16/18
01/16
08:27
01/16/18
08:27
Conference/Events
Energizer to hold a conference call »

Management discusses the…

SPB

Spectrum Brands

$120.48

-0.14 (-0.12%)

ENR

Energizer

$51.62

0.15 (0.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 29

    Jan

  • 30

    Jan

  • 31

    Jan

  • 08

    Feb

TPIC

TPI Composites

$20.98

0.28 (1.35%)

08:27
01/16/18
01/16
08:27
01/16/18
08:27
Initiation
TPI Composites initiated  »

TPI Composites initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

WLL

Whiting Petroleum

$29.78

0.06 (0.20%)

08:26
01/16/18
01/16
08:26
01/16/18
08:26
Upgrade
Whiting Petroleum rating change  »

Whiting Petroleum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RILY

B. Riley Financial

$18.95

0.55 (2.99%)

08:26
01/16/18
01/16
08:26
01/16/18
08:26
Hot Stocks
B. Riley Financial acquires 29% of bebe stores »

B. Riley Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KRYS

Krystal Biotech

$10.05

-0.45 (-4.29%)

08:25
01/16/18
01/16
08:25
01/16/18
08:25
Hot Stocks
Krystal Biotech granted patent for herpes simplex viral vectors »

Krystal Biotech announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAR

Avis Budget

$49.15

1.15 (2.40%)

08:25
01/16/18
01/16
08:25
01/16/18
08:25
Earnings
Avis Budget sees FY17 revenue about $8.85B, consensus 8.8B »

Avis Budget Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:25
01/16/18
01/16
08:25
01/16/18
08:25
General news
NY Empire State index preview: »

NY Empire State index…

CBT

Cabot

$67.24

0.84 (1.27%)

08:24
01/16/18
01/16
08:24
01/16/18
08:24
Recommendations
Cabot analyst commentary  »

Cabot price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DFS

Discover

$80.51

0.15 (0.19%)

08:24
01/16/18
01/16
08:24
01/16/18
08:24
Hot Stocks
Discover reports December charge-off rate 3.1% vs. 3.1% last month »

Reports December over 30…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

BTC

Bitcoin

, BITCOIN

Bitcoin

08:24
01/16/18
01/16
08:24
01/16/18
08:24
Periodicals
Bitcoin falls amid concerns over regulatory crackdown, Reuters reports »

Bitcoin has dropped 18%…

BTC

Bitcoin

BITCOIN

Bitcoin

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIMT

Aimmune

$39.43

0.78 (2.02%)

08:24
01/16/18
01/16
08:24
01/16/18
08:24
Recommendations
Aimmune analyst commentary  »

Aimmune Q1 data should be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GG

Goldcorp

$14.35

0.45 (3.24%)

08:23
01/16/18
01/16
08:23
01/16/18
08:23
Conference/Events
Goldcorp to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Feb

ATNX

Athenex

$15.87

0.15 (0.95%)

08:23
01/16/18
01/16
08:23
01/16/18
08:23
Hot Stocks
Athenex receives 'positive' feedback from FDA on design of Oraxol clinical trial »

Athenex announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IYT

iShares Transportation Average

$205.33

1.56 (0.77%)

08:20
01/16/18
01/16
08:20
01/16/18
08:20
Technical Analysis
iShares Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOW

ServiceNow

$138.19

0.61 (0.44%)

, CRM

Salesforce

$110.24

1.14 (1.04%)

08:20
01/16/18
01/16
08:20
01/16/18
08:20
Recommendations
ServiceNow, Salesforce analyst commentary  »

ServiceNow price target…

NOW

ServiceNow

$138.19

0.61 (0.44%)

CRM

Salesforce

$110.24

1.14 (1.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

XLK

Technology Select Sector SPDR

$66.81

0.39 (0.59%)

08:20
01/16/18
01/16
08:20
01/16/18
08:20
Technical Analysis
Technology Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DLR

Digital Realty

$105.78

-2.16 (-2.00%)

08:20
01/16/18
01/16
08:20
01/16/18
08:20
Upgrade
Digital Realty rating change  »

Digital Realty upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Feb

XLE

Energy Select Sector SPDR

$77.42

0.74 (0.97%)

08:20
01/16/18
01/16
08:20
01/16/18
08:20
Technical Analysis
Energy Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLY

Consumer Discretionary Sector SPDR

$105.03

1.34 (1.29%)

08:19
01/16/18
01/16
08:19
01/16/18
08:19
Technical Analysis
Consumer Discretionary Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QCOM

Qualcomm

$65.38

-0.05 (-0.08%)

, AVGO

Broadcom

$264.29

0.79 (0.30%)

08:19
01/16/18
01/16
08:19
01/16/18
08:19
Hot Stocks
Qualcomm urges shareholders to reject Broadcom's takeover proposal »

Qualcomm (QCOM) sent a…

QCOM

Qualcomm

$65.38

-0.05 (-0.08%)

AVGO

Broadcom

$264.29

0.79 (0.30%)

NXPI

NXP Semiconductors

$119.58

0.33 (0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

XLB

S&P Select Materials SPDR

$63.39

0.1 (0.16%)

08:19
01/16/18
01/16
08:19
01/16/18
08:19
Technical Analysis
S&P Select Materials SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLU

Utilities SPDR

$50.26

-0.29 (-0.57%)

08:19
01/16/18
01/16
08:19
01/16/18
08:19
Technical Analysis
Utilities SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.